Real-life experience (transgender)

Last updated

The real-life experience (RLE), sometimes called the real-life test (RLT), is a period of time or process in which transgender individuals live full-time in their identified gender role in order to be eligible to receive gender-affirming treatment. The purpose of the RLE has been to confirm that a given transgender person could function successfully as a member of said gender in society, as well as to confirm that they are sure they want to live as said gender for the rest of their life. A documented RLE was previously a requirement of many physicians before prescribing gender-affirming hormone therapy, and a requirement of most surgeons before performing gender-affirming surgery.

Contents

In September 2022, the World Professional Association for Transgender Health (WPATH) Standards of Care for the Health of Transgender and Gender Diverse People (SOC) Version 8 were released and removed the requirement of RLE for all gender-affirming treatments, including gender-affirming surgery. [1] Previous versions of the WPATH SOC had required completion of RLE for initiation of gender-affirming hormone therapy (3 months) and gender-affirming surgery (12 months). [2] [3]

Criteria

Standards of Care

Version 6

The sixth version of the World Professional Association for Transgender Health's (WPATH) Standards of Care (SOC), published in 2001, listed the parameters of the RLE as follows: [2]

  1. To maintain full or part-time employment;
  2. To function as a student;
  3. To function in community-based volunteer activity;
  4. To undertake some combination of items 1–3;
  5. To acquire a (legal) gender-identity-appropriate first name;
  6. To provide documentation that persons other than the therapist know that the patient functions in the desired gender role.

Version 7

The seventh version of the SOC, which was published in 2011, was more ambiguous, and did not list any specific parameters for the RLE. [3] Instead, they merely stated that the individual should be living full-time in their preferred gender role continuously for the duration of the RLE. They also stated that documentation of a name and/or gender marker change can be presented as a way of providing proof that the RLE has been completed, but did not state that a name and/or gender marker change was a requirement for completion of the RLE. [3] These changes may have been signs of WPATH moving away from gatekeeping, which the SOC had been criticized for. [4] [5] [6]

The seventh version of the SOC state that medical professionals should clearly document a patient's RLE in their medical chart, including the start date of living full-time for those preparing for GRS. [3] Sometimes surgeons may require proof that the RLE has been completed. [3] The SOC state that, if applicable, proof may be provided in the form of communication with individuals who have related to the patient in a gender identity-congruent role (such as, presumably, the patient's physician, therapist, boss, or a teacher), or as documentation of a legal name and/or gender marker change. [3]

Version 8

The eighth version of the SOC, published in 2022, removed all requirement of RLE for gender-affirming treatments, including gender-affirming surgery. [1]

Necessity

The SOC are followed by most medical professionals who specialize in the care of transgender individuals, and are the most widely followed clinical guidelines for the treatment of transgender persons in use. [3] Hence, the SOC criteria for HRT and GRS, including completion of an RLE when applicable, must usually be met for one who seeks such treatments to receive them.

As of the seventh version of the SOC, a three-month minimum requirement of RLE is no longer part of WPATH's recommended criteria for HRT. A referral letter alone from a qualified mental health professional now suffices. The SOC state: [3]

Although professionals may recommend living in the desired gender, the decision as to when and how to begin the real-life experience remains the person's responsibility.

With respect to mastectomy/chest reconstruction and breast augmentation, the seventh version of the SOC do not require an RLE for these procedures; nor is an RLE required for hysterectomy, salpingo-oophorectomy, or orchiectomy, or for other procedures such as facial feminization surgery and voice feminization surgery. However, for GRS, including metoidioplasty, phalloplasty, and vaginoplasty, one year of continuous RLE is a listed requirement. [3]

Previous versions of the SOC stated that an RLE for GRS was an absolute requirement that could not be skipped or ignored. [2] However, the seventh version of the SOC appears to be less stringent, and does not contain any such statements. In addition, WPATH emphasizes that the SOC are merely clinical guidelines, and are intended to be both flexible and modifiable to meet the circumstances of the patient and the preferences and judgement of the clinician. [3] Hence, the latest version of the SOC appears to allow for, in certain circumstances, the RLE to be skipped. [7]

Clinical practice in many places may be more or less stringent. In the United Kingdom, most National Health Service trusts will require two years of RLE before surgery, whereas in countries such as Thailand and Mexico, some surgeons may not require the completion of any RLE at all.[ citation needed ]

Criticism

Though the WPATH SOC's one-year RLE requirement prior to GRS has been widely followed by surgeons in the past, it has not gone without criticism. Like the previous three-month RLE requirement for hormone therapy, many transgender people have expressed displeasure with it and have declared that it is unnecessary. Alongside this, some private providers did not require RLE to prescribe hormone therapy. [8] Supporting such claims, physician and sexologist Anne Lawrence, in a paper presented at the XVII Harry Benjamin International Symposium on Gender Dysphoria in 2001, stated that there is little scientific evidence that a one-year RLE is necessary or sufficient for favorable outcomes following GRS. In addition, she presented the results of a study she conducted on a group of trans women in which she showed that GRS without a prior one-year RLE could be undergone without the subsequent expression of regret. She concluded that her results did not support the SOC requirement of a one-year RLE as an absolute requirement for GRS. [9]

The real life experience requirement for hormone therapy has also been described by some as "unreasonable" and "dangerous", due to the patient's physical appearance often not matching their declared gender prior to starting hormone therapy. [10] [11]

Further in support of the idea that a one-year RLE requirement prior to GRS is unnecessary, regret, as well as suicide, appear to be very rare in post-operative transgender people in general. In another study conducted by Anne Lawrence and published in 2003, she found that in a group of 232 post-operative trans women, none expressed outright regret, and only a few expressed even occasional regret. [12] In addition, a 2002 review of the literature reported that there is less than a 1% rate of regret, and a little more than a 1% rate of suicide, among post-operative transgender people; [13] for comparison, the rate of suicide in the general population is only about 1%, [14] while the suicide attempt rate of the transgender population as a whole was around 41% per a 2013 publication. [15]

Amnesty International emphasized in 2017 that the RLE has been criticized by the Committee on the Elimination of Discrimination against Women for promoting stereotypical gender roles. [16]

Perhaps in response to such criticisms, the WPATH SOC Version 8 removed the requirement of RLE for all gender-affirming treatments. [1]

See also

Related Research Articles

Gender dysphoria (GD) is the distress a person experiences due to a mismatch between their gender identity—their personal sense of their own gender—and their sex assigned at birth. The term replaced the previous diagnostic label of gender identity disorder (GID) in 2013 with the release of the diagnostic manual DSM-5. The condition was renamed to remove the stigma associated with the term disorder.

Gender-affirming surgery is a surgical procedure, or series of procedures, that alters a person's physical appearance and sexual characteristics to resemble those associated with their identified gender. The phrase is most often associated with transgender health care and intersex medical interventions, although many such treatments are also pursued by cisgender and non-intersex individuals. It is also known as sex reassignment surgery, gender confirmation surgery, and several other names.

<span class="mw-page-title-main">Harry Benjamin</span> German/American endocrinologist and sexologist

Harry Benjamin was a German-American endocrinologist and sexologist, widely known for his clinical work with transgender people.

The World Professional Association for Transgender Health (WPATH), formerly the Harry Benjamin International Gender Dysphoria Association (HBIGDA), is a professional organization devoted to the understanding and treatment of gender identity and gender dysphoria, and creating standardized treatment for transgender and gender variant people. WPATH was founded in September 1979 by endocrinologist and sexologist Harry Benjamin, with the goal of creating an international community of professionals specializing in treating gender variance.

The Standards of Care for the Health of Transgender and Gender Diverse People (SOC) is an international clinical protocol by the World Professional Association for Transgender Health (WPATH) outlining the recommended assessment and treatment for transgender and gender-diverse individuals across the lifespan including social, hormonal, or surgical transition. It often influences clinicians' decisions regarding patients' treatment. While other standards, protocols, and guidelines exist – especially outside the United States – the WPATH SOC is the most widespread protocol used by professionals working with transgender or gender-variant people.

<span class="mw-page-title-main">Trans man</span> Man assigned female at birth

A trans man is a man who was assigned female at birth. Trans men have a male gender identity, and many trans men undergo medical and social transition to alter their appearance in a way that aligns with their gender identity or alleviates gender dysphoria.

Gender transition is the process of changing one's gender presentation or sex characteristics to accord with one's internal sense of gender identity – the idea of what it means to be a man or a woman, or to be non-binary, genderqueer, bigender, or pangender, or to be agender (genderless). For transgender and transsexual people, this process commonly involves reassignment therapy, with their gender identity being opposite that of their birth-assigned sex. Transitioning might involve medical treatment, but it does not always involve it. Cross-dressers, drag queens, and drag kings tend not to transition, since their variant gender presentations are generally only adopted temporarily.

Gender dysphoria in children (GD), also known as gender incongruence of childhood, is a formal diagnosis for children who experience significant discontent due to a mismatch between their assigned sex and gender identity. The diagnostic label gender identity disorder in children (GIDC) was used by the Diagnostic and Statistical Manual of Mental Disorders (DSM) until it was renamed gender dysphoria in children in 2013 with the release of the DSM-5. The diagnosis was renamed to remove the stigma associated with the term disorder.

Feminizing hormone therapy, also known as transfeminine hormone therapy, is hormone therapy and sex reassignment therapy to change the secondary sex characteristics of transgender people from masculine or androgynous to feminine. It is a common type of transgender hormone therapy and is used to treat transgender women and non-binary transfeminine individuals. Some, in particular intersex people, but also some non-transgender people, take this form of therapy according to their personal needs and preferences.

<span class="mw-page-title-main">LGBT people in prison</span> Lesbian, gay, bisexual, transgender and queer people in prison

Lesbian, gay, bisexual, transgender and queer (LGBTQ) people face difficulties in prison such as increased vulnerability to sexual assault, other kinds of violence, and trouble accessing necessary medical care. While much of the available data on LGBTQ inmates comes from the United States, Amnesty International maintains records of known incidents internationally in which LGBTQ prisoners and those perceived to be lesbian, gay, bisexual or transgender have suffered torture, ill-treatment and violence at the hands of fellow inmates as well as prison officials.

<span class="mw-page-title-main">Transsexual</span> People experiencing a gender identity inconsistent with their assigned sex

A transsexual person is someone who experiences a gender identity that is inconsistent with their assigned sex, and desires to permanently transition to the sex or gender with which they identify, usually seeking medical assistance to help them align their body with their identified sex or gender.

<span class="mw-page-title-main">Trans woman</span> Woman assigned male at birth

A trans woman is a woman who was assigned male at birth. Trans women have a female gender identity and may experience gender dysphoria. Gender dysphoria may be treated with gender-affirming care.

Puberty blockers are medicines used to postpone puberty in children. The most commonly used puberty blockers are gonadotropin-releasing hormone (GnRH) agonists, which suppress the natural production of sex hormones, such as androgens and estrogens. In addition to their use in treating precocious puberty, which involves puberty occurring at an unusually early age in children, puberty blockers are also used for transgender children to delay the development of unwanted sex characteristics, so as to allow transgender youth more time to explore their gender identity.

Transgender hormone therapy, also called hormone replacement therapy (HRT) or gender-affirming hormone therapy (GAHT), is a form of hormone therapy in which sex hormones and other hormonal medications are administered to transgender or gender nonconforming individuals for the purpose of more closely aligning their secondary sexual characteristics with their gender identity. This form of hormone therapy is given as one of two types, based on whether the goal of treatment is masculinization or feminization:

Transgender health care includes the prevention, diagnosis and treatment of physical and mental health conditions, as well as gender-affirming care, for transgender individuals. A major component of transgender health care is gender-affirming care, the medical aspect of gender transition. Questions implicated in transgender health care include gender variance, sex reassignment therapy, health risks, and access to healthcare for trans people in different countries around the world.

Detransition is the cessation or reversal of a transgender identification or of gender transition, temporarily or permanently, through social, legal, and/or medical means. The term is distinct from the concept of 'regret', and the decision may be based on a shift in gender identity, or other reasons, such as health concerns, social pressure, or discrimination and stigma.

Facial masculinization surgery (FMS) is a set of plastic surgery procedures that can transform the patient's face to exhibit typical masculine morphology. Cisgender men may elect to undergo these procedures, and in the context of transgender people, FMS is a type of facial gender confirmation surgery (FGCS), which also includes facial feminization surgery (FFS) for transgender women.

<span class="mw-page-title-main">Genspect</span> Organization opposing transgender rights

Genspect is an international group founded in June 2021 by psychotherapist Stella O'Malley that has been described as gender-critical. Genspect is known for criticizing and opposing gender-affirming care, as well as social and medical transition for transgender people. Genspect opposes allowing transgender people under 25 years old to transition, and opposes laws that would ban conversion therapy on the basis of gender identity. Genspect also endorses the unproven concept of rapid-onset gender dysphoria (ROGD), which proposes a subclass of gender dysphoria caused by peer influence and social contagion. ROGD has been rejected by major medical organisations due to its lack of evidence and likelihood to cause harm by stigmatizing gender-affirming care.

The history of transgender people, their rights, legislation concerning them, and transgender healthcare in Finland dates from the earliest records in the 19th century.

The legal status of gender-affirming surgery and gender-affirming hormone therapy varies by jurisdiction, often interacting with other facets of the legal status of transgender people. Key considerations include whether people are allowed to get such surgeries, at what ages they are allowed to if so, and whether surgeries are required in order for a gender transition to be legally recognized. As of 2007, the countries that perform the greatest number of gender-affirming surgeries are Thailand and Iran.

References

  1. 1 2 3 Coleman, E.; et al. (19 August 2022). "Standards of Care for the Health of Transgender and Gender Diverse People, Version 8". International Journal of Transgender Health . 23 (sup1): S1–S259. doi: 10.1080/26895269.2022.2100644 . ISSN   2689-5269. PMC   9553112 . PMID   36238954.
  2. 1 2 3 Harry Benjamin International Gender Dysphoria Association (January–March 2001). "Standards of Care for Gender Identity Disorders, Sixth Version" (PDF). International Journal of Transgenderism. 5 (1). Archived from the original (PDF) on June 10, 2007.
  3. 1 2 3 4 5 6 7 8 9 10 World Professional Association for Transgender Health (September 2011), Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Seventh Version (PDF), archived from the original (PDF) on 2016-01-06
  4. ↑ Peggy J. J. Kleinplatz (23 April 2012). New Directions in Sex Therapy: Innovations and Alternatives. CRC Press. pp. 666–667. ISBN   978-1-136-33332-3 . Retrieved 8 September 2012.
  5. ↑ Jack Drescher; Dan Karasic (5 September 2006). Sexual and Gender Diagnoses of the Diagnostic and Statistical Manual (DSM): A Reevaluation. Psychology Press. pp. 54–55. ISBN   978-0-7890-3214-0 . Retrieved 8 September 2012.
  6. ↑ Julia Serano (20 May 2009). Whipping Girl: A Transsexual Woman on Sexism and the Scapegoating of Femininity. Seal Press. pp. 116, 119–126. ISBN   978-0-7867-4791-7 . Retrieved 8 September 2012.
  7. ↑ Jacques, Juliet (23 January 2012). "A Transgender Journey: Are You Experienced?". The Guardian . Retrieved 8 September 2012.
  8. ↑ Am I Trans Enough for GenderGP's Assessment? Yes, You Are! (Website), GenderGP Transgender Services, November 9, 2021{{citation}}: CS1 maint: location missing publisher (link)
  9. ↑ Lawrence, Anne (November 4, 2001), SRS Without a One Year RLE: Still No Regrets (Paper), XVII Harry Benjamin International Symposium on Gender Dysphoria, Galveston, Texas, archived from the original on June 23, 2018, retrieved June 2, 2018{{citation}}: CS1 maint: location missing publisher (link)
  10. ↑ Unger, Cecile (2016). "Hormone therapy for transgender patients". Transnational Andrology and Urology. 5 (6): 877–884. doi: 10.21037/tau.2016.09.04 . PMID   28078219.
  11. ↑ Cavanaugh, Timothy (2016). "Informed Consent in the Medical Care of Transgender and Gender-Nonconforming Patients". AMA Journal of Ethics. 18 (11): 1147–1155. doi:10.1001/journalofethics.2016.18.11.sect1-1611. PMID   27883307.
  12. ↑ Lawrence AA (August 2003). "Factors associated with satisfaction or regret following male-to-female sex reassignment surgery". Arch Sex Behav. 32 (4): 299–315. doi:10.1023/A:1024086814364. PMID   12856892. S2CID   9960176.
  13. ↑ Michel A, Ansseau M, Legros JJ, Pitchot W, Mormont C (October 2002). "The transsexual: what about the future?". Eur. Psychiatry. 17 (6): 353–62. doi:10.1016/S0924-9338(02)00703-4. hdl: 2268/181518 . PMID   12457746. S2CID   36381355.
  14. ↑ Värnik P (March 2012). "Suicide in the world". Int J Environ Res Public Health. 9 (3): 760–71. doi: 10.3390/ijerph9030760 . PMC   3367275 . PMID   22690161.
  15. ↑ Moody C, Smith NG (July 2013). "Suicide protective factors among trans adults". Arch Sex Behav. 42 (5): 739–52. doi:10.1007/s10508-013-0099-8. PMC   3722435 . PMID   23613139.
  16. ↑ "Amnesty International Public Statement – Index: IOR 10/7293/2017 – Stop Trans Pathologisation Worldwide" (PDF). www.amnesty.org. 2017-10-20.

Further reading

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.